Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Tinostamustine

Small molecule · Inhibitor of histone deacetylases and DNA · developed by Mundipharma Research

Phase 2/3 Most advanced trial
1 Registered trials

What is Tinostamustine?

Tinostamustine is a fusion molecule combining the alkylating agent bendamustine with the pan-HDAC inhibitor vorinostat. It inhibits histone deacetylases and alkylates DNA, inducing chromatin remodeling and tumor cell apoptosis. It is studied in glioblastoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
EDO-S101
Drug type
Small molecule
Targets
histone deacetylases, DNA
Mechanism
Inhibitor of histone deacetylases and DNA
Pathways
chromatin remodeling, gene expression modulation, unfolded protein response
Therapy area
Oncology
Developer
Mundipharma Research Limited
In trials of
BHVN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
29DKI2H2NY

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03970447 Phase 2/3 Glioblastoma Recruiting BHVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.